Ali-Jackson Kamil 4

What Happened
Ali-Jackson Kamil, a director of Rigel Pharmaceuticals (RIGL), sold 2,500 shares on May 26, 2026. The shares were disposed at $29.17 per share for a total proceeds of $72,925. This was a sale (code S) and, as a disposal, is generally considered routine rather than a corporate-positive signal.

Key Details

• Transaction date: 2026-05-26; reported on Form 4 filed 2026-05-28 (within the typical two-business-day reporting window).
• Price and size: 2,500 shares at $29.17 per share; total proceeds $72,925.
• Shares owned after transaction: Not specified in the provided filing.
• Footnote: The sale was effected pursuant to a 10b5‑1 trading plan adopted by the reporting person on November 7, 2025 (pre-arranged trading plan).
• Transaction type: Sale (S) — reported as an open-market or private sale.

Context

• A 10b5‑1 plan indicates the trade was pre-scheduled and is often used by insiders to avoid questions about timing; it does not necessarily reflect a change in the insider’s view of the company.
• For retail investors, purchases typically carry more informational weight than routine sales; this single scheduled sale should be viewed as a routine disposal unless other insider actions or company news suggest otherwise.